Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.58 |
| ▸ | HTR1A | P08908 | 7/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.58 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2778482 | 0.98 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL3126596 | 0.89 | HTR2C (0.48) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL5318468 | 0.87 | GPR6 (0.50) | SLC6A2HTR1ASLC6A3HRH1 | |
| SCHEMBL29555 | 0.87 | GRIN1 (0.43) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL83203 | 0.86 | SLC6A2 (0.62) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| Hydrochloric Acid SCHEMBL69817 | 0.85 | HTR1A (0.60) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL5383787 | 0.83 | HTR1A (0.51) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL6103269 | 0.83 | HTR1A (0.51) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL5369367 | 0.83 | SLC6A2 (0.51) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL15566745 | 0.83 | HTR1A (0.51) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042755-A1 | GPR6 INVERSE AGONISTS | MAPLIGHT THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025233901-A1 | ACTIVATORS OF PYRUVATE KINASE ISOFORM M2 AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-13 | — | — | WO | disclosed |
| EP-4568668-A2 | GPR6 INVERSE AGONISTS | MapLight Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024036288-A2 | GPR6 INVERSE AGONISTS | MAPLIGHT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-08-30 | — | — | US | disclosed |
| EP-3105230-B1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | GPR6, GPR3, GPR68 | SLC6A2 2424/4885HTR1A 129/4885SLC6A3 1647/4885 |
| US-20260042755-A1 | GPR6 INVERSE AGONISTS | GPR6, GPR3, GPR4 | SLC6A2 348/4885HTR1A 313/4885SLC6A3 374/4885 |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | GPR6, GPR3, GPR68 | SLC6A2 2424/4885HTR1A 129/4885SLC6A3 1647/4885 |
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | GPR6, GPR65, GPR55 | SLC6A2 1324/4885HTR1A 185/4885SLC6A3 1367/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | SLC6A2 4025/4885HTR1A 4269/4885SLC6A3 4203/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | SLC6A2 1256/4885HTR1A 745/4885SLC6A3 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.